The sellside’s most controversial products
Drugs prompting the most divergent opinions on outlook include Pfizer and Vir’s Covid-19 offerings and Biogen’s Aduhelm.
ESC 2021 – finerenone’s song gets a little sweeter
Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Lilly’s Protomer deal shows innovation in diabetes is not dead
Lilly and Novo look set for a battle in glucose-sensitive insulin, and other areas too.
Novo bets against Crispr for amyloidosis
Novo moves into amyloidosis not long after Intellia made a splash here.
Sigilon hold hurts ahead of key haemophilia meeting
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Alzheimer’s and Covid-19 developers make hay on the stock markets
Big risers include Eli Lilly, Biogen, Moderna and Biontech.
